For example, through the analysis of nine gene promoters, Hoque et al. found that 69% of bladder cancer patients had methylation in at least one of four genes (CDKN2A, ARF, MGMT and GSTP1), whereas the control patients had no such methylation detectable [28]. The gene discussed is CDKN2A; the disease is urinary bladder cancer.